Clinical Trials Logo

Clinical Trial Summary

This is a prospective case - control study to investigate ATP level in induced sputum and cough sensitivity to ATP in subjects with refractory chronic cough. 60 refractory chronic cough and 30 matched healthy controls were recruited. Medical history records, cough severity assessment, induced sputum for ATP measurement, ATP evoked cough and capsaicin evoked cough were completed. The difference of sputum ATP level between patients and control and the correlation between sputum ATP level and cough sensitivity to ATP were analyzed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05265871
Study type Observational
Source The First Affiliated Hospital of Guangzhou Medical University
Contact Kefang Lai, MD
Phone +86 18928868231
Email klai@vip.163.com
Status Not yet recruiting
Phase
Start date April 15, 2022
Completion date May 16, 2023

See also
  Status Clinical Trial Phase
Completed NCT03282591 - Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough Phase 2
Completed NCT03407014 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Phase 2
Completed NCT02476890 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Phase 2
Recruiting NCT05599191 - A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 3
Recruiting NCT03662269 - Indomethacin for Refractory Chronic Cough Phase 3
Recruiting NCT05962151 - Refractory Chronic Cough Improvement Via NAL ER (RIVER) Phase 2
Recruiting NCT05110144 - Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough Phase 2
Active, not recruiting NCT04882943 - COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
Enrolling by invitation NCT05733533 - A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough Phase 2
Completed NCT02349425 - A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) Phase 2
Recruiting NCT05600777 - A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2) Phase 3
Completed NCT05628740 - Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 Phase 1
Not yet recruiting NCT06213363 - A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough Phase 1/Phase 2
Completed NCT02412020 - Treatment of Refractory Chronic Cough With PA101 Phase 2
Completed NCT04678206 - Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 2
Completed NCT02612623 - An 8-Week Refractory Chronic Cough Study (MK-7264-021) Phase 2
Completed NCT02612610 - A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) Phase 2
Completed NCT02397460 - Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) Phase 2